iShares Biotechnology ETFIBB
Type
ETF
Peer group
US equity: Healthcare
Net assets
$8.1B
Expense ratio
0.44%
1-year return
+51.7%
3 years, a year
+17.9%
5 years, a year
+4.2%
12-month yield
0.16%
Holdings
258
What it aims to do.
The iShares Biotechnology ETF (the Fund ) seeks to track the investment results of an index composed of U.S.-listed equities in the biotechnology sector.
Top 10 holdings.
| Holding | % of fund |
|---|---|
| BlackRock Funds III | 9.66% |
| GILD Gilead Sciences, Inc. | 7.75% |
| AMGN Amgen, Inc. | 7.51% |
| VRTX Vertex Pharmaceuticals, Inc. | 7.44% |
| REGN Regeneron Pharmaceuticals, Inc. | 7.21% |
| ALNY Alnylam Pharmaceuticals, Inc. | 3.99% |
| INSM Insmed, Inc. | 3.20% |
| ARGX Argenx SE | 3.07% |
| BIIB Biogen, Inc. | 2.46% |
| NTRA Natera, Inc. | 2.41% |
More on IBB.
- IBB overview
- IBB holdings
- IBB risk
- IBB costs
- IBB money in and out
- IBB share classes
- Compare IBB with other funds
Returns after fees, from the fund's SEC filings up to Aug 2026. Past returns are not a promise. Not financial advice.